AIM ImmunoTech to Discuss Second Quarter 2024 Financial Results on August 16, 2024, and Host Conference Call and Webcast

by Barry101 | Aug 13, 2024 | Press Release

OCALA, Fla., Aug. 13, 2024 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), announced today that management will host a conference call and webcast to discuss the Company’s Q2 2024 operational and financial...

AIM ImmunoTech Announces Release of the Next CEO Corner Segment

by Barry101 | Jul 29, 2024 | Press Release

OCALA, Fla., July 29, 2024 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced the next CEO Corner segment has been published on the Company’s website. In the CEO Corner segment, AIM Chief Executive...

AIM Announces New Positive Data on Ampligen’s Anti-Tumor Potential When Used as Part of a Combination Therapy

by Barry101 | Jul 24, 2024 | Press Release

OCALA, Fla., July 24, 2024 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the publication of new pre-clinical data concerning the company’s drug Ampligen as part of a combinational therapy in the...

AIM ImmunoTech Announces Release of the Next CEO Corner Segment

by Barry101 | Jul 3, 2024 | Press Release

OCALA, Fla., July 03, 2024 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the next CEO Corner segment has been published on the Company’s website. For the CEO Corner segment, AIM Chief Executive...

AIM ImmunoTech to Participate in the Virtual Investor Pitch Conference

by Barry101 | Jun 10, 2024 | Press Release

Live video webcast on Monday, June 17th at 1:00 PM ETOCALA, Fla., June 10, 2024 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced that Thomas K. Equels, MS JD, Chief Executive Officer of AIM will...